

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Two new triterpenoids from *Lycopodium obscurum* L.

Ying-Hong Zhao^a; Tie-Zhong Deng^b; Yu Chen^b; Xiang-Ming Liu^b; Guang-Zhong Yang^b

^a Xishuangbanna Prefecture National Medicine Research Institute, Jinghong, China ^b Laboratory for Natural Product Chemistry, College of Pharmacy, South Central University for Nationalities, Wuhan, China

Online publication date: 11 August 2010

To cite this Article Zhao, Ying-Hong , Deng, Tie-Zhong , Chen, Yu , Liu, Xiang-Ming and Yang, Guang-Zhong(2010) 'Two new triterpenoids from *Lycopodium obscurum* L.', Journal of Asian Natural Products Research, 12: 8, 666 – 671

To link to this Article: DOI: 10.1080/10286020.2010.493881

URL: <http://dx.doi.org/10.1080/10286020.2010.493881>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ORIGINAL ARTICLE

Two new triterpenoids from *Lycopodium obscurum* L.

Ying-Hong Zhao^a, Tie-Zhong Deng^b, Yu Chen^b, Xiang-Ming Liu^b
and Guang-Zhong Yang^{b*}

^aXishuangbanna Prefecture National Medicine Research Institute, Jinghong 666100, China;

^bLaboratory for Natural Product Chemistry, College of Pharmacy, South Central University for Nationalities, Wuhan 430074, China

(Received 9 February 2010; final version received 12 May 2010)

Two new onoceroid triterpenoids, (3 α ,8 β ,14 α ,21 β)-26,27-dinoroceran-3,8,14,21-tetrol (**1**) and 26-nor-8 β -hydroxy- α -onocerin (**2**), were isolated from *Lycopodium obscurum* L. Their structures were elucidated on the basis of spectroscopic analyses.

Keywords: *Lycopodium*; *Lycopodium obscurum* L.; onoceroid triterpenoid; Lycopodiaceae

1. Introduction

Serratane-type triterpenoids represent a large family of plant constituents obtained from the club moss belonging to Lycopodiaceae. These structurally diverse pentacyclic triterpenes possess unusual skeletons with a seven-membered C-ring, and a C=C double bond between C (14) and C (15), and O-functionalities at C (3) and C (21) [1]. Many *Lycopodium* plants contain α -onocerin, and it was deduced that serratane-type triterpenoids came from single protonation of α -onocerin [2]. Serratane-type triterpenoids exhibit well-documented pharmacological properties, such as cancer chemopreventive activity [3] and inhibitory effects against *Candida albicans* secreted aspartic proteases [4]. *Lycopodium obscurum* L. has been used in China as a traditional folk medicine for the treatment of contusion, dysmenorrhea, quadriplegia, arthritic pain [5], and has been reported to be a source of serratenes [6,7]. During our search for biologically

active secondary metabolites, we investigated the chemical constituents of *L. obscurum* L. Here, we describe the isolation and structural elucidation of two new naturally occurring triterpenoids (Figure 1).

2. Results and discussion

Compound **1** was isolated as a white amorphous powder. The molecular formula of **1** was deduced as C₂₈H₅₀O₄, which was confirmed by HR-EI-MS at *m/z* 432.3591 corresponding to a fragmental ion [M – H₂O]⁺. The ¹H NMR spectrum of **1** displayed the presence of six tertiary methyls [δ_{H} 0.93 (s), 1.27 (s), 1.40 (s)], two coinciding equatorial oxygenated methines [δ_{H} 3.68 (2H, br s, H-3, 21)], and two coinciding equatorial oxygenated methines [δ_{H} 4.36 (2H, br s, H-8, 14)]. The ¹³C NMR and DEPT spectra of **1** displayed 14 carbon signals, including two oxygenated methines (δ_{C} 75.3, 66.5), three methyls, five methylenes, two methines, as well as

*Corresponding author. Email: yanggz888@126.com




Figure 1. Structures of compounds **1** and **2**.

two quaternary carbons, suggesting the presence of a symmetric structure within this molecule. A comparison of ^{13}C NMR spectral data of **1** with those of the known compound (3 β ,8 β ,14 α ,21 α)-26,27-dinoroceran-3,8,14,21-tetrol, isolated from *Lycopodium japonicum* [8], revealed similar carbon signals, except for the chemical shifts of C(1) or (19), C(3) or (21), and C(5) or C(17). This suggested that the plane structure of **1** should be the same as that of (3 β ,8 β ,14 α ,21 α)-26,27-dinoroceran-3,8,14,21-tetrol, except for the orientation of C(3) or (21)-OH. A comparison of ^{13}C NMR spectral data of **1** with those of (3 β ,8 β ,14 α ,21 α)-26,27-dinoroceran-3,8,14,21-tetrol indicated that C(3) or C(21) containing the axial hydroxyl group in **1** was more shielded (δ_{C} 75.3) than the latter containing the equatorial one (δ_{C} 78.4). The chemical shifts of C(1) or C(19) and C(5) or C(17) were also shielded by about 3.5 and 7.6 ppm, respectively, in **1** due to the γ -gauche interaction [9]. The assumption was further supported by the NOE correlations between Me(24) or Me

(29) (δ_{H} 0.93 (s)) and H-3 or H-21 (δ_{H} 3.68 (br s)), and the small coupling constant between H-2 and H-3 (Figure 2). From the above data, the structure of **1** was established as (3 α ,8 β ,14 α ,21 β)-26,27-dinoroceran-3,8,14,21-tetrol.

Compound **2**, which was obtained as a white amorphous powder, exhibited an $[\text{M} + \text{Na}]^+$ ion peak at m/z 469.3671 in the HR-FAB-MS, corresponding to the molecular formula $\text{C}_{29}\text{H}_{50}\text{O}_3$. Its ^1H NMR spectrum showed six tertiary methyls [δ_{H} 0.69 (3H, s), 0.75 (3H, s), 0.77 (3H, s), 0.91 (3H, s), 0.96 (6H, s)], three oxygenated methines [δ_{H} 3.13 (1H, dd, $J = 11.4, 4.2$ Hz), 3.18 (1H, dd, $J = 10.2, 6.0$ Hz), 3.92 (1H, br s)], and one exomethylene [δ_{H} 4.83 (1H, s), 4.64 (1H, s)]. The ^{13}C NMR and DEPT spectra of **2** displayed 29 carbon signals, including an exomethylene (δ_{C} 149.3, 107.8), three oxygenated methines (δ_{C} 79.7, 79.5, 67.9), six methyls, 10 methylenes, four methines, as well as four quaternary carbons. All the above data suggested that **2** should be tetracyclic triterpenoids having OH and six




Figure 2. Key ROESY correlations of compound **1**.




Figure 3. Key ROESY correlations of compound **2**.

tertiary Me groups, such as α -onocerin [10]. On comparison of the ^{13}C NMR spectral data of **2** with those of 26-nor-8-oxo- α -onocerin [7], it was found that except for the presence of one more oxygenated methine (δ_{C} 67.9) instead of the carbonyl group (δ_{C} 211.7) in **2**, the ^{13}C NMR spectral data of **2** were nearly superimposed on those of 26-nor-8-oxo- α -onocerin. Thus, the carbonyl group in 26-nor-8-oxo- α -onocerin was replaced by the hydroxyl group in **2**. Three hydroxyl groups of **2** were located at C (3), C (8), and C (21), which were further supported by the HMBC correlations between H-3/C-2 (δ_{C} 28.6), C-4 (δ_{C} 40.0), and C-24 (δ_{C} 16.6); H-8/C-7 (δ_{C} 36.8) and C-9 (δ_{C} 56.2); and H-21/C-20 (δ_{C} 30.8), C-22 (δ_{C} 40.2), C-29 (δ_{C} 16.3), and C-30 (δ_{C} 28.9). The relative configuration of **2** was derived from the ROESY spectrum. The ROESY correlations of H-3/H₃-23 and H-8/H-9 (Figure 3) suggested that 3-OH and 8-OH were β -oriented. The 21-OH was deduced to be in the α -position, which was based on the ROESY correlations of H-21/H₃-30. Thus, the structure of compound **2** was established as 26-nor-8 β -hydroxy- α -onocerin.

Compounds **1** and **2** were evaluated for their *in vitro* cytotoxic activities against KB (human oral carcinoma) cancer cell lines using the MTT assay method. Compound **2** exhibited weak cytotoxic activity with an IC_{50} value of 32.5 μM using fluorouracil as a positive control (IC_{50} = 15.9 μM). Compound **1** was inactive against tested cell lines.

3. Experimental

3.1 General experimental procedures

IR was carried out on a Nicolet NEXUS-6700 instrument. Optical rotations were measured with a Perkin-Elmer 341 polarimeter. NMR spectra were run on Bruker AM-400 and 600 spectrometers with TMS as an internal standard. EI-MS and HR-EI-MS were measured with a Finnigan MAT 95 instrument. FAB-MS and HRFABMS were carried out on a VG Autospec-3000 spectrometer. Thin-layer chromatography was performed on silica gel 60 GF₂₅₄, and column chromatography (CC) was carried out using silica gel (200–300 mesh) from Qingdao Haiyang Chemical Group Co., Qingdao, China and C₁₈ reverse-phase silica gel from YMC Co. Ltd Kyoto, Japan.

3.2 Plant material

The whole plant of *L. obscurum* L. was collected from Jianshi County, Hubei Province, China, and identified by Prof. Dingrong Wan, College of Pharmacy, South Central University for Nationalities.

3.3 Extraction and isolation

The air-dried whole plant of *L. obscurum* L. (12.3 kg) was powdered and then extracted with MeOH (25 liters) three times at room temperature. The MeOH extract (1.65 kg) was suspended in 3% tartaric acid/H₂O (pH = 3) and then partitioned with EtOAc. The EtOAc extract (890 g) was suspended in 90% H₂O/MeOH and then successively parti-

tioned with petroleum ether (PE), EtOAc, and *n*-BuOH. The EtOAc extract (324 g) was subjected to CC (silica gel, PE:acetone 9:1, 8:2, 7:3, 1:1, 3:7, 0:1, v/v) to give nine fractions (Fr.1–Fr.9). Fr.5 (10.9 g) was subjected to CC (silica gel, CHCl₃/acetone 1:0→1:1) to give five sub-fractions (Fr.5.1–Fr.5.5). Fr.5.4 (5.5 g) was subjected to CC (ODS, H₂O/MeOH 9:1→1:9) to give compound **1** (20 mg). Fr.5.3 (2.2 g) was subjected to CC (silica gel, cyclohexane/EtOAc 9:1→1:1) to give four subfractions

(Fr.5.3.1–Fr.5.3.4). Fr.5.3.2 (350 mg) was subjected to CC (ODS, H₂O/MeOH 7:3→3:7) to give compound **2** (40 mg).

3.3.1 (3 α ,8 β ,14 α ,21 β)-26,27-Dinoronocerane-3,8,14,21-tetrol (**1**)

A white amorphous powder; [α]_D = +24.5 (*c* = 0.200, MeOH); ¹H NMR and ¹³C NMR spectral data see Table 1; EI-MS *m/z* (rel. int.): 432 ([M]⁺ – H₂O, 2), 414 ([M]⁺ – 2H₂O, 29), 399 (34), 193 (46), 175 (100), 161 (32), 147 (27), 135 (44),

Table 1. ¹H NMR, ¹³C NMR, and HMBC spectral data of compound **1** (in C₅D₅N, δ in ppm).

No.	¹ H NMR	¹³ C NMR	HMBC
1	1.65 (1H, m) 1.89 (1H, m)	32.8	C (2), C (10)
2	1.81 (1H, m) 2.07 (1H, m)	26.1	C (4), C (10)
3	3.68 (1H, br s)	75.3	C (1), C (5), C (24)
4	–	38.2	
5	1.85 (1H, m)	49.4	C (10), C (23), C (25)
6	1.52 (1H, m) 1.96 (1H, m)	17.4	
7	1.69 (1H, m) 2.22 (1H, m)	36.6	
8	4.36 (1H, br s)	66.5	C (10)
9	1.32 (1H, m)	54.6	C (10), C (11)
10	–	38.1	
11	1.53 (1H, m) 2.11 (1H, m)	22.9	
12	1.53 (1H, m) 2.11 (1H, m)	22.9	
13	1.32 (1H, m)	54.6	
14	4.36 (1H, br s)	66.5	
15	1.69 (1H, m) 2.22 (1H, m)	36.6	
16	1.52 (1H, m) 1.96 (1H, m)	17.4	
17	1.85 (1H, m)	49.4	
18	–	38.1	
19	1.65 (1H, m) 1.89 (1H, m)	32.8	
20	1.81 (1H, m) 2.07 (1H, m)	26.1	
21	3.68 (1H, br s)	75.3	
22	–	38.2	
23	1.27 (3H, s)	29.2	C (3), C (4), C (5), C (24)
24	0.93 (3H, s)	22.7	C (3), C (4), C (5), C (23)
25	1.40 (3H, s)	16.6	C (1), C (5), C (9), C (10)
28	1.40 (3H, s)	16.6	
29	0.93 (3H, s)	22.7	
30	1.27 (3H, s)	29.2	

Table 2. ^1H NMR, ^{13}C NMR, and HMBC spectral data of compound **2** (in CD_3OD , δ in ppm).

No.	^1H NMR	^{13}C NMR	HMBC
1	0.82 (1H, m) 1.78 (1H, m)	38.5	
2	1.48 (2H, m)	28.6	
3	3.13 (1H, dd, $J = 11.4, 4.2$ Hz)	79.5	C (2), C (4), C (24)
4	—	40.0	
5	0.81 (1H, m)	56.1	C (4), C (6), C (10), C (24)
6	1.45 (1H, m) 1.75 (1H, m)	18.0	
7	1.41 (1H, m) 1.94 (1H, m)	36.8	
8	3.92 (1H, br s)	67.9	C (7), C (9)
9	0.86 (1H, m)	56.2	C (8), C (10), C (11)
10	—	40.3	
11	1.28 (1H, m) 1.53 (1H, m)	23.1	
12	1.16 (1H, m) 1.65 (1H, m)	24.2	
13	1.55 (1H, m)	57.9	C (12), C (14), C (18)
14	—	149.3	
15	1.97 (1H, m) 2.38 (1H, d, $J = 13.2$ Hz)	39.0	C (14)
16	1.30 (1H, m) 1.68 (1H, m)	25.2	
17	1.13 (1H, m)	56.6	C (16), C (18), C (22), C (30)
18	—	39.5	
19	1.58 (2H, m)	38.6	
20	1.34 (2H, m)	30.8	
21	3.18 (1H, dd, $J = 10.2, 6.0$ Hz)	79.7	C (20), C (22), C (29), C (30)
22	—	40.2	
23	0.96 (3H, s)	28.9	C (3), C (4), C (24)
24	0.91 (3H, s)	16.6	C (3), C (4), C (23)
25	0.75 (3H, s)	16.2	C (1), C (5), C (10)
27	4.64 (1H, s) 4.83 (1H, s)	107.8	C (13), C (14), C (15)
28	0.69 (3H, s)	15.2	C (17), C (18)
29	0.77 (3H, s)	16.3	C (21), C (22), C (30)
30	0.96 (3H, s)	28.9	C (22), C (29)

121 (36), 107 (29), 95 (38), 81 (32), 69 (30), 55 (21); HR-EI-MS m/z : 432.3591 ($[\text{M}]^+ - \text{H}_2\text{O}$) (calcd for $\text{C}_{28}\text{H}_{48}\text{O}_3$, 432.3604), 414.3515 ($[\text{M}]^+ - 2\text{H}_2\text{O}$) (calcd for $\text{C}_{28}\text{H}_{46}\text{O}_2$, 414.3498).

1465, 1391, 1089, 1030, 929, 894. ^1H NMR and ^{13}C NMR spectral data see Table 2; FAB-MS: m/z 469 $[\text{M} + \text{Na}]^+$; HR-FAB-MS: m/z 469.3671 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{29}\text{H}_{50}\text{O}_3\text{Na}$, 469.3657).

3.3.2 26-Nor-8 β -hydroxy- α -onocerin (2)

A white amorphous powder; $[\alpha]_{\text{D}} = +30.4$ ($c = 0.395$, MeOH); IR (KBr) ν_{max} (cm^{-1}): 3383, 2933, 2851, 1643,

Acknowledgement

This work was financially supported by the Academic Team of South Central University for Nationalities: Ethno-Medicine Research and Development (XTZ09010).

References

- [1] H. Zhou, Y.S. Li, X.T. Tong, H.Q. Liu, S.H. Jiang, and D.Y. Zhu, *Nat. Prod. Res.* **18**, 453 (2004).
- [2] Y. Inubushi, Y. Tsuda, T. Sano, T. Konita, S. Suzuki, H. Ageta, and Y. Otake, *Chem. Pharm. Bull.* **15**, 1153 (1967).
- [3] R. Tanaka, T. Minami, Y. Ishikawa, H. Tokuda, and S. Matsunaga, *Chem. Biodiver.* **1**, 878 (2004).
- [4] Z.Z. Zhang, H.N. Elsohly, M.R. Jacob, D.S. Pasco, L.A. Walker, and A.M. Clark, *J. Nat. Prod.* **65**, 979 (2002).
- [5] Jiangsu New Medical College, *Dictionary of Chinese Traditional Medicines* (Shanghai Science and Technology Press, Shanghai, 1977), p. 553.
- [6] X. Cai, D.J. Pan, G.Y. Xu, S. Haruo, and F. Kazuo, *Acta Chim. Sin.* **50**, 60 (1992).
- [7] X. Cai, D.J. Pan, and G.Y. Xu, *Acta Chim. Sin.* **47**, 1025 (1989).
- [8] J. Yan, X.M. Zhang, Z.R. Li, L. Zhou, J.C. Chen, L.R. Sun, and M.H. Qiu, *Helv. Chim. Acta* **88**, 240 (2005).
- [9] S.B. Mahato and A.P. Kundu, *Phytochemistry* **37**, 1517 (1994).
- [10] G.F. Pauli, *Planta Med.* **66**, 299 (2000).